Chagas’ disease has become a progressive emerging disease in the United States. In South and Central America, the disease may affect over 18 million people. Typically, the causative agent, Trypanosoma cruzi, may not immediately kill the host, but the parasite keeps the host in check, in order to maximize transmission and therefore, prolong its life cycle. The mammalian host can gradually develop illness from an acute or mild form of the disease to a latent stage, to a chronic stage. There is significant mortality due to the Acute and Chronic stages of this disease. In particular, CCC is thought to be caused by an autoimmune attack upon nerve and/or heart tissue (1).
Recognition of this parasite as a potential threat to the US blood supply was in 1992 when several biopharmaceutical companies developed diagnostic tests to identify this disease (2). In 1995 the FDA accepted a 510(k) diagnostic test (Enzyme Immunoassay) for Chagas’ disease (3; 4). Progressive improvements to identify several highly antigenic T. cruzi molecules reactive with human chagasic antiserum were made in subsequent years (2006–2011); the Association for the Advancement of Blood and Biotherapies (AABB), the FDA, CDC, and WHO have now recognized this disease as one of the 13 donor screening assays for Infectious Agents.
Presently there are no vaccines against Chagas’ disease and therapeutic agents (benznidazole) have only recently (2017) been FDA approved for use in children ages 2 to 12 years old with Chagas’ disease. Side effects are common, frequent, and severe with increasing age. In this regard, alternative methods for treatment are necessary. Our primary focus has been to search and identify highly antigenic T. cruzi molecules reactive with human chagasic antiserum (3; 5). To this end, one cloned gene from T. cruzi amastigotes was chosen, sequenced and found to be identical to the repetitive antigen Clone 36, "Antigen 36"(6).
Search of GenBank using our DNA sequence translated by the TFASTA program revealed identity of Human Ro52 with the translated sequence in the second reading frame of Ag36. Direct comparison of the Ag36 DNA sequence with Ro52 DNA sequence revealed 70% identity in one sequence of 44 nucleotides between the Ag36 DNA sequence and TRIM21, the gene for human Ro52 (7). Here we query TRIM genes, and other innate mammalian immune genes, for any such extended sequence identities using established bioinformatic tools (8).
TRIM genes are a large family of mammalian and vertebrate genes, which share homologous domains (9; 10). Many of these genes code for E3 Ubiquitin ligases, and many of them function in regulating innate immunity and immunity to viruses and cancer (11; 12). For example, TRIM21 is an E3 Ubiquitin ligase that modifies transcription factors for alpha and beta interferons and other cytokines, thereby dampening (or stimulating) Interferon gene transcription (13; 14). Knock out of TRIM21 in mice strains showed that they were susceptible to tissue inflammation and systemic autoimmunity after injury induced by skin tagging (15). We proposed that the partial gene homology between TRIM21 and Ag36 may cause RNA interference, mRNA silencing, or down-regulation of Ro52, leading to the autoimmunity of CCC (16). We also proposed that for the parasite, the interference could be beneficial during its invasion of macrophages by blocking TRIM21 stimulation of innate immunity. It would be useful to explore any similarities between Ag 36 and the genes of other mammalian TRIM21 genes to validate the sequence similarity observed between human TRIM21 and the T. cruzi Ag36 gene. In this work, we extend the comparison of DNA sequences of Ag36 to eighteen additional mammalian TRIM21 sequences, using the Needleman-Wunsch (NW) algorithm to determine partial sequence similarities, and to observe their correlation with mammalian phylogeny.
In 2021, DeCuir and his team (17) published the complete sequence of the nuclear genome of T. cruzi (strain SC43). This sequence and others enabled (a) description of T. cruzi genes homologous to Ag36; (b) finding that there are human TRIM family genes similar to them; and (c) discovery that T. cruzi Ag36 gene sequence is similar to human Interferon alpha and beta genes.